1Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001,344:783-792. 被引量：1
2Cook-Bruns N. Retrospective analysis of the safety of Hereeptin immunotherapy in metastatic breast cancer. Oncology, 2001,61:S58-S66. 被引量：1
3Pietras RJ, Pegram MD, Finn RS, et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene, 1998, 17:2235-2249. 被引量：1
4Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage Ⅱ or Ⅲ breast cancer: a pilot study. J Clin Oncol, 2003, 21:46-53. 被引量：1
5Van Pelt AE, Mohsin S, Elledge RM, et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer, 2003, 4:348-353. 被引量：1
6Schiffhauer LM, Griggs JJ, Ahrendt GM, et al. Docetaxd and trastuzumab as primary systemic therapy for HER-2/neu-overexpressing breast cancer. Proc Am Soc Clin Oncol, 2003, 22:242. 被引量：1
7Hurley J, Doliny P, Silva O, et al. Neoadjuvant Hereeptin/taxotere/cisplatin in the treatment of locally advanced and inflammatory breast cancer., P roc AmSoc Clin Oncol, 2002, 21:50a. 被引量：1
8Jahanzeb M, Brufsky A, Erban J, et al.Dose-dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbineand trastuzumab with growth factor support. J Clin Oncol, 2005,23:S591. 被引量：1
9Baselga J, Gianni L, Geyer C, et al. Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol, 2004, 31 :S51-S57. 被引量：1
